Hikma is a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets it serves through the development, manufacturing and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (MENA) region, the United States and Europe. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index.

Type
Public
HQ
London, GB
Founded
1978
Size (employees)
8,339 (est)+16%
Website
hikma.com
Hikma Pharmaceuticals was founded in 1978 and is headquartered in London, GB
Report incorrect company information

Hikma Pharmaceuticals Office Locations

Hikma Pharmaceuticals has an office in Cairo, London, Beirut, Dubai and in 1 other location
London, GB (HQ)
13 Hanover Square
Show all (5)
Report incorrect company information

Hikma Pharmaceuticals Financials and Metrics

Hikma Pharmaceuticals Financials

Hikma Pharmaceuticals's revenue was reported to be £1.51 b in FY, 2016 which is a 51.2% increase from the previous period.
GBP

Revenue (FY, 2016)

1.5 b

Revenue growth (FY, 2015 - FY, 2016), %

51.2%

Gross profit (FY, 2016)

762.1 m

Gross profit margin (FY, 2016), %

50.6%

Net income (FY, 2016)

122.1 m

EBITDA (FY, 2016)

306.1 m

EBIT (FY, 2016)

233.4 m

Market capitalization (31-Oct-2017)

2.8 b

Closing share price (31-Oct-2017)

11.4

Cash (31-Dec-2016)

125.2 m

EV

2.8 b
Hikma Pharmaceuticals's current market capitalization is £2.8 b.
GBPY, 2016

EV/EBITDA

9 x

EV/EBIT

11.8 x

EV/CFO

12.2 x

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information